A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

NACompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Chronic Kidney Disease
Interventions
OTHER

K2CG chewing gum (20mg chitosan)

All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14

OTHER

K2CG chewing gum (60mg chitosan)

"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"

Trial Locations (4)

78215

Renal Associates, PA, San Antonio

80230

Denver Nephrologists, PC, Denver

83642

Pacific Renal Research Institute, Meridian

85284

Southwest Clinical Reserach Institute, LLC, Tempe

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CM&D Pharma Limited

INDUSTRY

lead

Denver Nephrologists, P.C.

OTHER

NCT01475760 - A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter